Search | Clinical Trials Finder

Conditions: Non-Small Cell Lung Cancer
Interventions: SID530, Taxotere; Drug
Lead sponsor: SK Chemicals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Miami, Florida • Canton, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Insulin glargine, Insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 52
States / cities: Little Rock, Arkansas • Anaheim, California • Concord, California + 44 more

Conditions: Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Bladder Cancer
Interventions: Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Blood Flow Restriction, Growth Hormone, Strength Outcomes, Arginine
Interventions: BFR, Arginine, Placebo Pill; Procedure · Dietary Supplement
Lead sponsor: University of Mary Hardin-Baylor; Other
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Belton, Texas

Conditions: Neovascular Age-related Macular Degeneration (nAMD)
Interventions: Faricimab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Santa Ana, California • Orlando, Florida • Winter Haven, Florida + 8 more

Conditions: Anemia, Aplastic, Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Kostmann Syndrome
Interventions: Allogeneic stem cell transplant; Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Crohn's Disease
Interventions: Adalimumab; Biological
Lead sponsor: Abbott; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 26
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 22 more

Conditions: Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma, Blood and Marrow Transplant (BMT)
Interventions: Autologous peripheral blood stem cells (auto-PBSC) transplantation, Allogeneic peripheral blood stem cells (allo-PBSC) transplantation, Filgrastim, Cyclophosphamide, Melphalan, Cyclosporine, Total lymphoid irradiation, Rabbit anti-thymocyte globulin, Mycophenolate Mofetil 250mg, Solumedrol, Diphenhydramine, Acetaminophen, Hydrocortisone; Procedure · Drug · Radiation + 1 more
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Prostate Cancer
Interventions: EC1169, EC0652; Drug · Other
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: Scottsdale, Arizona • New Haven, Connecticut • New Orleans, Louisiana + 3 more

Conditions: Colorectal Cancer
Interventions: FOLFIRI, E7820, Bevacizumab; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Denver, Colorado • Berkeley Heights, New Jersey • Mount Holly, New Jersey + 3 more

Conditions: Advanced Melanoma
Interventions: Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice; Drug
Lead sponsor: Immunocore Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 25
States / cities: Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 19 more

Conditions: Tumors
Interventions: NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod, NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo; Drug
Lead sponsor: Nina Bhardwaj; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Child, Only, Disabilities Multiple, Medication Interaction, Medication Compliance, Medication Administered in Error
Interventions: Pediatric Medication Therapy Management (pMTM); Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 2 Years to 18 Years
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
Interventions: Fenfluramine, Placebo; Drug
Lead sponsor: Zogenix, Inc.; Industry
Eligibility: 1 Year to 35 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non Malignant Diseases, Immunodeficiencies, Hemoglobinopathies
Interventions: Reduced-Intensity Conditioning; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Months to 25 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Type 1 Diabetes
Interventions: Rapid-Acting Insulin, Long acting insulin; Drug
Lead sponsor: Emory University; Other
Eligibility: 7 Years to 15 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Community-acquired Pneumonia
Interventions: Heparin; Drug
Lead sponsor: University of Manitoba; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 6
States / cities: Chicago, Illinois • Jefferson, Louisiana • Portland, Maine + 3 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Paclitaxel and carboplatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 56
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Springdale, Arkansas + 47 more

Conditions: HIV Infection
Interventions: Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r), Raltegravir (RAL), VRC01, Dolutegravir (DTG), VRC07-523LS; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 48 Hours
Enrollment: 1,120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2031
U.S. locations: 21
States / cities: La Jolla, California • Los Angeles, California • Aurora, Colorado + 13 more

Conditions: Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Breast Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions: cytology specimen collection procedure, laboratory biomarker analysis; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Plaque Psoriasis
Interventions: Ixekizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 59
States / cities: Birmingham, Alabama • Anaheim, California • Beverly Hills, California + 52 more

Conditions: Metastatic Renal Cell Carcinoma
Interventions: NST using MUD for metastatic renal cell carcinoma; Procedure
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 5
States / cities: Los Angeles, California • Gainesville, Florida • Minneapolis, Minnesota + 2 more

Conditions: Prostate Cancer
Interventions: Ketoconazole, Hydrocortisone; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

Study to Evaluate SID 530 Compared to Taxotere

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)

Sacituzumab Govitecan Plus EV in Metastatic UC

The Effect of Blood Flow Restriction With and Without Arginine on Physical Performance and Growth Hormone

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Phase 1 of EC1169 In Patients With Recurrent MCRPC

FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

Pediatric Medication Therapy Management Trial

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

A Clinical Trial of Alternating and Intermittent Regimens of 2',3'-Dideoxycytidine and 3'-Azido-3'-Deoxythymidine in the Treatment of Patients With AIDS and Advanced ARC

Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders

A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma

Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy